SUMO1 Antibody (21C7) [Unconjugated]

20 µg of total protein (cellular lysate) obtained from HCT-116 cells, HEK293 cells, or HeLa cells was separated on a reducing 4-20% SDS-PAGE gel. Western blots were developed using PVDF membranes and alpha -SUMO1 (A-722) mAb primary at 0.5 µg/ml followed by HRP-labeled anti-mouse (R&D Systems # HAF007) secondary antibody at 1:2000 dilution. Both SUMO1 protein and SUMOylated RanGAP (confirmed by reprobing membrane with alpha -RanGAP antibody) were detected on the blot.

Product Discontinued

SUMO1 Antibody (21C7) [Unconjugated] Summary

• Immunogen: Purified, recombinant human SUMO1
  Accession # P63165
• Specificity: This antibody detects endogenous, human SUMOylated proteins in Western blots. Cross-reactive against murine and rat proteins.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: SUMO1
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot 0.1-0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Store the unopened product at -20 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Storage below -20 °C is not recommended. Do not use past expiration date.
• Buffer: Supplied as a solution in PBS containing Glycerol and Sodium Azide.
• Preservative: Sodium Azide

Notes

* Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to SDS for additional information and handling instructions.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SUMO1 Antibody (21C7) [Unconjugated]

• DAP1
• GAP modifying protein 1
• GAP-modifying protein 1
• GMP1SMT3CSMT3H3OFC10UBL1PIC1
• PIC1
• SENP2
• Sentrin
• small ubiquitin-related modifier 1
• SMT3 homolog 3
• SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)
• SMT3 suppressor of mif two 3 homolog 1 (yeast)
• SMT3
• SMT3C
• SMT3H3
• SUMO1
• SUMO-1
• Ubiquitin-homology domain protein PIC1
• ubiquitin-like 1 (sentrin)
• Ubiquitin-like protein SMT3C
• Ubiquitin-like protein UBL1
• UBL1

Background

Small Ubiquitin­like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post­translational modification process termed SUMOylation. Unlike ubiquitination, which targets proteins for degradation, SUMOylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All human SUMO proteins share a conserved ubiquitin-like domain and a C-terminal diglycine cleavage/attachment site. Human SUMO1, also known as Sentrin, UBL1, and SMT3C, is synthesized as a 101 amino acid (aa) propeptide that contains a four aa C­terminal prosegment. Following prosegment cleavage, the C­terminal glycine may be enzymatically attached to a lysine on a target protein. Human SUMO1 shares 100% sequence identity to SUMO1 from mouse. SUMO1 is the most unique of the four identified SUMO proteins and shares only 44%, 47%, and 41% sequence identity to SUMO2, SUMO3, and SUMO4, respectively.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: SUMO1
• Uniprot:
  • P63165()